Johnson & Johnson

Key TakeawaysIbrutinib combinations show higher efficacy rates compared to standard therapy alone. Two-year fixed-duration ibrutinib therapy contributes to sustained remission in untreated MCL...

Key TakeawaysSIMPONI’s expansion could offer a new standard of care for pediatric UC patients. The application reflects Johnson & Johnson’s strategic focus on...

Key TakeawaysImpella pumps reduce ventricular workload, promoting heart recovery in critical pediatric cases. Expanded indications cover a broader range of heart failure etiologies,...

Key TakeawaysStandardization will likely lead to more accurate reporting of surgical complications. Enhanced data collection can identify trends and inform preventative strategies. Integration...

Johnson & Johnson is set to unveil an extensive range of over 90 research abstracts at the 2024 American Society of Hematology Annual Meeting...

Johnson & Johnson has officially launched its latest pharmaceutical offering, Yuvanci Combination Tablets, aimed at treating patients with pulmonary arterial hypertension (PAH). This new...

Key TakeawaysEnhanced product offerings in shoulder, foot, and ankle soft tissue repairs. Increased support and resources for surgeons through advanced technologies. Strengthened market...

Key TakeawaysOTTAVA's compact design allows for integration into existing operating rooms without significant spatial adjustments. The twin motion feature facilitates seamless intraoperative repositioning,...

Key TakeawaysNipocalimab is the first and only therapy with FDA Breakthrough designation for Sjogren's disease. Phase 2 DAHLIAS study showed significant improvement in...

Key TakeawaysEmbrace diverse evidence synthesis techniques to enhance the quality of JCA dossiers. Recognize the importance of ITCs in addressing gaps left by...

Johnson & Johnson continues to blaze a trail in the field of neuroscience, reinforcing its commitment to addressing complex mental health challenges through innovation....

Key TakeawaysTREMFYA® (guselkumab) has shown superior efficacy in inducing remission for both biologic-naïve and biologic-refractory patients with Crohn's disease (CD) and ulcerative colitis...

Key TakeawaysNipocalimab, a first-of-its-kind FcRn blocker, shows sustained disease control in adolescents with generalized myasthenia gravis (gMG) over 24 weeks. Adolescents (ages 12-17)...

Key TakeawaysVOLT™ Plating System offers next-generation fracture management with improved stability, flexibility, and performance for orthopedic procedures. The system provides a wide array...

Key TakeawaysCARVYKTI® significantly improves overall survival in multiple myeloma patients. The treatment shows a 45% reduction in the risk of death compared to...